Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia.

International journal of clinical practice - 1 May 2021

Oka Satoko, Ono Kazuo, Nohgawa Masaharu

Abstract excerpt

AIM: Eltrombopag is a highly effective treatment for immune thrombocytopenia (ITP). Cases of durable remission after the discontinuation of eltrombopag in adult ITP have recently been reported; however, the frequency and mechanisms responsible for this phenomenon remain unknown. In the present study, we examined the phenotypes of lymphocytes in ITP to clarify whether they predict outcomes after the...

Topics

Join the communities discussing this publication.

Benzoates
Hydrazines
Lymphocytes
Phenotype
Purpura, Thrombocytopenic, Idiopathic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Source

Identifiers

PMID: 33529437
DOI: 10.1111/ijcp.14057

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia.PMID 33529437Read ↗

The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in ITPSemantic proximity Read ↗

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico ApproachSemantic proximity Read ↗

Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopeniaSemantic proximity Read ↗

Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.Semantic proximity Read ↗

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Immune thrombocytopenia: A review of upfront treatment strategies.Semantic proximity Read ↗

Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center ExperienceSemantic proximity Read ↗

Challenge for long-term discontinuation of immunosuppressants in children with idiopathic nephrotic syndrome: a single-center experience over 10 yearsSemantic proximity Read ↗

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.Semantic proximity Read ↗

Management of Refractory Immune Thrombocytopenia with Fostamatinib: A Case ReportSemantic proximity Read ↗

Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.Semantic proximity Read ↗

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.